Skip to main content
Caplight Logo









AnaCardio

AnaCardio

Private
StockholmHealthcare & Life Scienceshttps://anacardio.com

Last Round

Series B

Sep 30, 2026

Est. Valuation

$1.71M

Total Funding Raised

$104.16M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

AnaCardio operates in Healthcare & Life Sciences and is based in Stockholm. Its latest recorded funding round was a Series B round in September 2026.

AnaCardio is a clinical-stage biopharmaceutical company that develops novel drugs to treat heart failure.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

AnaCardio Comparables

Compare AnaCardio with similar companies based on industry and business-model similarity.

AnaCardio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cardurion Pharmaceuticals
85%
Thryv Therapeutics
82%
Windtree Therapeutics, Inc.
77%
Book a demo to see all comparables

For institutional investors. Book with your work email.

AnaCardio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 30, 2026
Series A ExtensionJan 9, 2025
Series ASep 7, 2022
VC RoundFeb 3, 2022
SeedJun 17, 2021
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Philipp Mathieu

Chief Financial Officer

Executive Team

Johan Sjödahl

Chief Operating Officer

Executive Team

For institutional investors. Book with your work email.

AnaCardio Investors

Notable investors and investment history

AnaCardio investors
InvestorRounds
InnovestorSeries B
Innovestor Life ScienceSeries B
3B FUTURE Health FundSeries B, Series A
IndustrifondenSeries A Extension, Series B, VC Round, Series A
Novo HoldingsSeries A Extension, Series B
Karolinska Development ABSeries A, VC Round, Seed
Pureos BioventuresSeries B, Series A Extension
Book a demo to see all 10 investors

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 30, 2026

    $71M round led by Novo Holdings

  • Sep 12, 2026

    Monthly visitors increased 241% MoM.

Book a demo to see all signals

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • receives_financingOct 3, 2026

    AnaCardio AB announced a $19M Series A extension in Jan '25; the announcement did not disclose a share price or valuation.

  • receives_financingSep 30, 2026

    AnaCardio AB raised a $62.5M Series A Plus to develop new therapies for heart failure in Sweden.

  • receives_financingSep 30, 2026

    AnaCardio AB completed a $71M Series B financing in Sweden on Sep 30th '26, co-led by Novo Holdings and the Ljungström family office to fund AC01 through Phase 2b development.

Book a demo to see all news

For institutional investors. Book with your work email.

AnaCardio Filings

Explore SEC and related filing metadata, where available.

AnaCardio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about AnaCardio's valuation, stock price, and market status.

Is AnaCardio a public or private company?

AnaCardio is a private company.

What is the current stock price of AnaCardio?

AnaCardio is a private company, so its shares have no public market price. Caplight tracks AnaCardio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is AnaCardio worth (valuation)?

AnaCardio's valuation is estimated at $1.7M based on funding round data.

Can I buy AnaCardio stock?

AnaCardio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was AnaCardio's last funding round?

AnaCardio's most recent funding round was Series B on September 30, 2026.

Who are the main investors in AnaCardio?

Key investors in AnaCardio include Industrifonden, Novo Holdings, Karolinska Development AB, Pureos Bioventures, Flerie AB.

Will AnaCardio IPO soon?

No public IPO plans have been announced for AnaCardio.

How can I track AnaCardio secondary market activity?

Caplight tracks bids, offers, and trades in AnaCardio's shares on secondary markets.

Firmographic Details

HeadquartersStockholm
Employee Range22
Year Founded2021
Last FundingSep 30, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?